| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | DNA mismatch repair gene; DNA mismatch repair protein PMS2; HNPCC4; PMS1 protein homolog 2 |
| Entrez GeneID | 5395 |
| WB Predicted band size | Calculated MW: 96 kDa; Observed MW: 110 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human PMS2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于PMS2抗体的参考文献及其摘要概括：
1. **文献名称**: "Immunohistochemistry of DNA mismatch repair enzymes in curatively resected colorectal carcinoma"
**作者**: Gologan A, et al.
**摘要**: 该研究评估了PMS2抗体在结直肠癌组织中的免疫组化应用，验证其作为林奇综合征筛查工具的可靠性，发现PMS2表达缺失与微卫星不稳定性(MSI)高度相关。
2. **文献名称**: "PMS2 expression in colorectal cancer: The confluence of technical and pathological variables"
**作者**: Shia J, et al.
**摘要**: 研究分析了不同PMS2抗体克隆(如EPR3947)的特异性，指出抗体选择和组织处理方式可能影响检测结果，强调标准化操作对诊断准确性的重要性。
3. **文献名称**: "Comparison of monoclonal and polyclonal antibodies in detecting Lynch syndrome-associated PMS2 defects"
**作者**: Overbeek LI, et al.
**摘要**: 对比单克隆与多克隆PMS2抗体的性能，发现单克隆抗体(如16-4)在识别生殖细胞突变导致的蛋白缺失中特异性更高，减少假阳性风险。
4. **文献名称**: "The role of PMS2 immunohistochemistry in the evaluation of endometrial carcinomas"
**作者**: Mills AM, et al.
**摘要**: 探讨PMS2抗体在子宫内膜癌中的表达模式，证实其联合其他错配修复蛋白(MLH1/MSH6)检测可提高林奇综合征筛查的敏感性。
The PMS2 antibody is a crucial tool in molecular pathology and cancer research, primarily targeting the PMS2 protein—a key component of the DNA mismatch repair (MMR) system. PMS2 forms a heterodimer with MLH1. functioning to correct base-pair mismatches and insertion-deletion loops during DNA replication. Defects in PMS2. often due to germline or somatic mutations, disrupt MMR activity, leading to microsatellite instability (MSI) and increased cancer risk, notably in Lynch syndrome-associated cancers (e.g., colorectal, endometrial).
In clinical diagnostics, PMS2 immunohistochemistry (IHC) helps identify MMR-deficient tumors by detecting loss of protein expression. This aids in Lynch syndrome screening, tumor classification, and predicting responses to immunotherapy. PMS2 staining patterns are interpreted alongside MLH1. MSH2. and MSH6 due to functional interdependencies. However, antibody specificity challenges exist, as PMS2 shares homology with other MMR proteins and exhibits pseudogene interference. Recent antibody clones (e.g., EPR3947. A16-4) show improved specificity through refined epitope targeting.
Research applications include studying MMR mechanisms, genetic instability, and tumorigenesis. Proper validation using positive/negative controls and molecular correlation (e.g., MSI testing) remains essential for accurate interpretation. Ongoing efforts focus on standardizing PMS2 detection protocols to enhance diagnostic reliability across laboratories.
×
